Go to the list of all blogs
Anna G's Avatar
published in Blogs
Oct 31, 2022
TickeronGET DAILY SIGNALS
AbbVie (ABBV, $145.47) beats Q3 expectations, despite revenue miss

AbbVie (ABBV, $145.47) beats Q3 expectations, despite revenue miss

AbbVie Inc. ‘s third quarter earnings came in at $3.66 per share for the third quarter of 2022 (up +29.3% from the year-ago quarter), exceeding the Zacks Consensus Estimate of $3.56 per share.

Revenues rose +3.3% year-over-year to $14.81 billion, missing the Zacks Consensus Estimate of $14.92 billion.

In immunology, AbbVie’s flagship drug Humira experienced a 3.9% sales growth to $5.56 billion on an operational basis. Sales in the U.S. grew +7.4% to $4.96 billion, vs. the -16.8% decline in ex-U.S. market sales.

AbbVie narrowed the full-year 2022 adjusted earnings per share guidance range to $13.84-$13.88, from the prior guidance of $13.78-$13.98. The Zacks Consensus Estimate is $13.89 per share.

Related Ticker: ABBV

ABBV saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for ABBV moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 69 similar instances where the indicator exited the overbought zone. In 35 of the 69 cases the stock moved lower. This puts the odds of a downward move at 51%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ABBV moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 17 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 40%.

The Moving Average Convergence Divergence Histogram (MACD) for ABBV turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 20 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 42%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.

ABBV broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on ABBV as a result. In 51 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.

Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 217 of 356 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.

The Aroon Indicator entered an Uptrend today. In 224 of 351 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.

The Tickeron Seasonality Score of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-87.784) is very low in comparison to the industry average of (-1.235). ABBV has a moderately high P/E Ratio (83.285) as compared to the industry average of (21.492). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.038) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).

The Tickeron Price Growth Rating for this company is 7 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 216.97B. The market cap for tickers in the group ranges from 4.8K to 1.26T. LLY holds the highest valuation in this group at 1.26T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 2%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 7%. SNY experienced the highest price growth at 12%, while MDCX experienced the biggest fall at -24%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 63%. For the same stocks of the Industry, the average monthly volume growth was 22% and the average quarterly volume growth was 39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 33
Price Growth Rating: 40
SMR Rating: 59
Profit Risk Rating: 58
Seasonality Score: 19 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a research-based pharmaceutical company

Industry PharmaceuticalsMajor

Industry
Pharmaceuticals Major
Address
1 North Waukegan Road
Phone
+1 847 932-7900
Employees
57000
Web
https://www.abbvie.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
Xerox Holdings Corporation (XRX) stock price surged +114% over the past 30 days, driven primarily by a strong Q1 2026 revenue beat from the Lexmark acquisition. Over the past quarter, XRX is up +17%, recovering from mid-period lows amid volatile trading and financial concerns.
ExxonMobil reported GAAP net earnings of $4.2 billion, or $1.00 per diluted share (EPS), down from $7.7 billion, or $1.76 per share, in Q1 2025. Adjusted earnings excluding identified items reached $4.9 billion, or $1.16 per share, surpassing consensus estimates around $1.00 to $1.07.
AbbVie (ABBV, $145.47) beats Q3 expectations, despite revenue miss